These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 3555788

  • 1. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E, Fiere D, Treille-Ritouet D, Adeleine P, Guyotat D, Sebban C, Vuvan H, Viala JJ.
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [Abstract] [Full Text] [Related]

  • 2. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 3. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N.
    Leukemia; 1989 Feb 15; 3(2):115-21. PubMed ID: 2911205
    [Abstract] [Full Text] [Related]

  • 4. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M.
    Leukemia; 1994 Jan 15; 8(1):11-5. PubMed ID: 8289475
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR, Weiner RS, Moore JO, Omura GA, Bartolucci AA, Stagg M.
    Leukemia; 1995 Sep 15; 9(9):1456-60. PubMed ID: 7544851
    [Abstract] [Full Text] [Related]

  • 6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 15; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 7. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W, Michlmayr G, Gerhartz H, Illinger H, König H, Düllmann J, Keilhauer R, Moldrzyk D.
    Onkologie; 1989 Feb 15; 12(1):8-10. PubMed ID: 2654791
    [Abstract] [Full Text] [Related]

  • 8. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F, Fernández-Barbieri MA, Santarelli MT, Matus-Ridley M, Rosso A, Negri-Aranguren P, Cerutti I, Gomel M, Kvicala R.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [Abstract] [Full Text] [Related]

  • 9. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N, Usui N, Yano S, Yahagi Y, Takei Y, Sugiyama K, Takahara S, Ogasawara Y, Yamaguchi Y, Saito T, Yokoyama H, Aiba K.
    Jpn J Clin Oncol; 2011 Jun 15; 41(6):820-4. PubMed ID: 21415001
    [Abstract] [Full Text] [Related]

  • 10. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y, Sampi K, Kuraishi Y, Okabe K, Tamura K, Mizoguchi H, Saito H, Masaoka T, Ogawa M.
    Int J Hematol; 1999 Jul 15; 70(1):20-5. PubMed ID: 10446490
    [Abstract] [Full Text] [Related]

  • 11. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
    Hewlett JS, Chen T, Balcerzak SP, Gutterman JU, Costanzi JJ, Amare M.
    Arch Intern Med; 1985 Jun 15; 145(6):1006-12. PubMed ID: 3890786
    [Abstract] [Full Text] [Related]

  • 12. Progress in acute myelogenous leukemia.
    Gale RP.
    Cancer Treat Rep; 1981 Jun 15; 65 Suppl 4():87-92. PubMed ID: 7049383
    [Abstract] [Full Text] [Related]

  • 13. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 14. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
    Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, Parikh PM.
    Natl Med J India; 2005 Dec 15; 18(1):12-5. PubMed ID: 15835484
    [Abstract] [Full Text] [Related]

  • 15. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May 15; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 16. Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
    Holowiecki J, Rudzka E, Jarczok K, Holowiecka B, Krawczyk M, Duraj M, Japa J.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983 May 15; 110(6):792-7. PubMed ID: 6200390
    [Abstract] [Full Text] [Related]

  • 17. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A.
    Blood; 1999 Jun 15; 93(12):4116-24. PubMed ID: 10361108
    [Abstract] [Full Text] [Related]

  • 18. Consolidation therapy without maintenance for acute non-lymphoblastic leukaemia.
    Roberts MM, Juttner CA, Blunden RW, Horvath N, To LB, Ho JQ, Dart GW, Kimber RJ.
    Med J Aust; 1988 Feb 15; 148(4):181-3. PubMed ID: 3340044
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 15; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.